The purpose of this study is to evaluate the safety of OTO-104 in subjects with unilateral Meniere's disease. The effectiveness of OTO-104 to reduce the symptoms of Meniere's disease will also be evaluated.
Meniere's disease is a debilitating disorder of the inner ear which includes symptoms such as vertigo, tinnitus, hearing loss and aural fullness. Meniere's disease may result from an imbalance of fluid in the inner ear. Several studies have shown that corticosteroids may help manage this imbalance yet the effect does not last very long. OTO-104 is a longer lasting corticosteroid which could provide significant benefit to patients with Meniere's disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
44
OTO-104 3 mg dose cohort, single intratympanic injection.
Placebo arm will be conducted in parallel with each OTO-104 dose cohort.
Sequential dose cohort escalation to OTO-104 12 mg dose cohort will occur pending the safety evaluation of 28 day follow up safety data for the OTO-104 3 mg dose cohort. OTO-104 12mg dose cohort is also a single intratympanic injection.
House Ear Institute
Los Angeles, California, United States
University of California, San Diego
San Diego, California, United States
The primary objective of this study is to evaluate the safety and tolerability of two ascending OTO-104 doses relative to placebo. Safety assessments will be performed for 3 months post single intratympanic injection of OTO-104 or placebo.
Time frame: 3 months
The secondary objective of this study is to evaluate the clinical activity of two OTO-104 doses relative to placebo. Change in baseline for vertigo frequency will be evaluated with descriptive statistics.
Time frame: 3 months
The impact of tinnitus on activities of daily living will be measured.
Time frame: 3 months
Hearing loss in the affected ear will be measured by audiometric examination.
Time frame: 3 months
Quality of life will be measured by patient reported questionnaire.
Time frame: 3 months
Severity of vertigo episodes will be measured by the patient reported vertigo score.
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Colorado Otolaryngology Associates
Colorado Springs, Colorado, United States
Silverstein Institute
Sarasota, Florida, United States
Northwestern University, Feinberg School of Medicine, Otolaryngology
Chicago, Illinois, United States
Mass Eye & Ear Infirmary
Boston, Massachusetts, United States
University of Michigan Hospitals, Dept. of Otolaryngology
Ann Arbor, Michigan, United States
Michigan Ear Institute
Farmington Hills, Michigan, United States
St Louis University
St Louis, Missouri, United States
New York Eye and Ear Infirmary
New York, New York, United States
...and 5 more locations